Merck & Co., Inc.

Company: Merck & Co., Inc.
Ticker: MRK

Submit Your Information

If you suffered a loss on your Merck & Co., Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Last Name*

Email*

Phone*

City

State

Country

Total # of shares

First Purchase Date

Last Purchase Date

Estimated Loss Range

Check here if you still hold any shares.

Check here if you are a current or former employee of the company.

Check here if you purchased any shares before

Additional Comments

Background

On October 22, 2026, an early release of closely watched clinical trial results for the Moderna and Merck’s joint experimental cancer vaccine appeared on medical news website Oncology Central but were taken down shortly afterward. According to the briefly published report, combining the Moderna and Merck’s personalized mRNA cancer vaccine with Merck’s blockbuster immunotherapy Keytruda reduced the risk of melanoma returning or death by 42% compared with Keytruda alone.

On this news, Merck stock fell as much as $1.44 or 0.96%, during intraday trading on October 22, 2026.

Submit Your Information